Brief: Compass Pathways And Greenbrook Tms Enter Into Three-Year Research Collaboration Agreement
Jan 5 (Reuters) - Compass Pathways PLC CMPS.O :
* COMPASS PATHWAYS AND GREENBROOK TMS ENTER INTO THREE-YEAR
RESEARCH COLLABORATION AGREEMENT
* THREE-YEAR RESEARCH COLLABORATION AGREEMENT TO EXPLORE
DELIVERY
MODELS FOR INVESTIGATIONAL COMP360 PSILOCYBIN TREATMENT
* COMPASS HAS COMMENCED A PHASE 3 CLINICAL PROGRAM OF
COMP360 IN
TRD
* COMPASS INTENDS TO APPLY FOR FDA APPROVAL UPON COMPLETION
OF
CLINICAL TRIALS.
Source text for Eikon: ID:nGNX4fDZyN
Further company coverage: CMPS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications